Drug Trial Radar · NCT03730051
Dotarem vs Gadobutrol Contrast for Breast MRI
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Mar 1, 2021
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- University of Massachusetts, WorcesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guerbet
- First posted
- Nov 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this randomized clinical trial, the investigators expect to demonstrate that the MRI contrast agent Dotarem is not less effective in contrast enhancement of breast lesions then Gadavist. Participants will be randomized to receive either Dotarem or Gadavist. In all cases, inclusion criteria will require patients having undergone or scheduled or most likely to be scheduled to undergo tissue sampling with histology results available. The patients will be prospectively and consecutively identified such that the majority of patients included will have been diagnosed with breast cancer, while including benign disease in the minority of patients in each arm. Following randomized enrollment, quantitative, semi-quantitative and qualitative image analysis will be performed to objectively assess for differences in image quality and diagnostic value.
Conditions
- Breast Diseases
Interventions
Gadoterate meglumineDrug
Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
GadobutrolDrug
Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of breast MRITime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UMass Medical School
Worcester, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.